NewAmsterdam Pharma Company N.V. announced that it will present new clinical and preclinical data highlighting the potential for Obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 92ndCongress and the National Lipid Association (NLA) 2024 Scientific Sessions, taking place on May 26 - 29 in Lyon, France and May 30 - June 2 in Las Vegas, Nevada, respectively. Presentation details are as follows: EAS 92ndCongress, Lyon, France, May 26-29, 2024 Title: Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the OCEAN and ROSE2 Studies Session Name: 0390 - SaaG Session: New tricks of HDL Oral Presentation Session Date and Time: May 27, 2024, 2:42 PM- 2:49 PM CET (8:42 AM-8:49 AM ET) Location:Station 7 Title: Obicetrapib Demonstrates Significant Reductions of Lp(a) on Top of High-Intensity Statins Session Name: 0601 - SaaG Session: Late-breaking lipids Oral Presentation Session Date and Time:May 28, 2024, 2:12 PM- 2:19 PM CET (8:12 AM-8:19 AM ET) Location: Station 8 Title: Obicetrapib Alone and in Combination with Ezetimibe Reduces Non-HDL-Cholesterol by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion in APOE 3-Leiden.CETP Mice Session Name: 0660- SaaG Session: Breaking updates in lipid-lowering treatments Oral Presentation Session Date and Time: May 28, 2024, 3:17-3:24 CET (9:17 AM-9:24 AM ET) Location: Station 3 Title: Obicetrapib Alone and in Combination with Ezetimibe Reduces Atherosclerotic Lesion Size and Severity in APOE 3-Leiden.CETP Mice Session Name: 0660- SaaG Session: Breaking updates in lipid-lowering treatments Oral Presentation Session Date and Time: May 28, 2024, 3:24-3:31 CET (9:24 AM-9:31 AM ET) Location: Station 3 Title: Obicetrapib does not Accumulate in Adipose Tissue: Results from Studies in Man and Non-Human Primates Flatboard Presentation Date: May 27 and Tuesday, May 28, 2024 NLA 2024 Scientific Sessions, Las Vegas, Nevada, May 30-June 2, 2024 Title: Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins Abstract/Poster #: 128 Date and Time:May 31, 2024, 2:30 PM- 2:55 PM PT (5:30 PM-5:55 PM ET) Location: Poster Hall Monitor # 30 Title: Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles Abstract/Poster #: 138 Date and Time: May 31, 2024, 2:30 PM- 2:55 PM PT (5:30 PM-5:55 PM ET) Location: Poster Hall Monitor # 22 Title: Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates Abstract/Poster #: 127 Date and Time:Friday, May 31, 2024, 2:30 PM- 2:55 PM PT (5:30 PM-5:55 PM ET) Location: Poster Hall Monitor # 18 Title: Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the OCEAN and ROSE2 Studies Abstract/Poster #: 140 Date and Time: May 31, 2024, 2:30 PM- 2:55 PM PT (5:30 PM-5:55 PM ET) Location: Poster Hall Monitor # 15 Title: Assessment of Unmet Clinical Needs and Healthcare Resource Use Among Statin-Treated Patients with or at Risk of Developing ASCVD Abstract/Poster #: 139 Date and Time:May 31, 2024, 2:30 PM- 2:55 PM PT (5:30 PM-5:55 PM ET) Location: Poster Hall Monitor # 12 Presentation Title: Obicetrapib Alone and with Ezetimibe Reduces Non-HDL-C by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion Abstract/Poster #: 141 Oral Presentation Session: Session V Date and Time:June 1, 2024, 11:05 AM- 11:55 AM PT (2:05-2:55 PM ET).